Results 131 to 140 of about 52,343 (282)
Inhibition of iRhom1 by CD44-targeting nanocarrier for improved cancer immunochemotherapy
Nature CommunicationsThe multifaceted chemo-immune resistance is the principal barrier to achieving cure in cancer patients. Identifying a target that is critically involved in chemo-immune-resistance represents an attractive strategy to improve cancer treatment.
Zhangyi Luo +17 more
doaj +1 more source
Induction of Cyp2e1 contributes to asparaginase-induced hepatocyte sensitization to lipotoxicity
Acta Pharmaceutica Sinica BOne of the leading therapies for acute lymphoblastic leukemia (ALL) is the chemotherapeutic agent PEGylated E. coli-derived-l-asparaginase (PEG-ASNase).
Yin Zhu +7 more
doaj +1 more source
Pharmacogenetics of clozapine response [PDF]
, 2000 Johannes Schumacher +4 more
openalex +1 more source
Opportunities and Challenges of Population Pharmacogenomics
Annals of Human Genetics, Volume 89, Issue 5, Page 384-397, September 2025.ABSTRACT Pharmacological responses can vary significantly among patients from different ethnogeographic backgrounds. This variability can, at least in part, be attributed to population‐specific genetic patterns in genes involved in drug absorption, distribution, metabolism, and excretion, as well as in genes associated with drug‐induced toxicity ...
Yitian Zhou +3 more
wiley +1 more source
Pharmacogenetics and the Blood–Brain Barrier: A Whirlwind Tour of Potential Clinical Utility
Future PharmacologyGenetic factors influence medication response (pharmacogenetics), affecting the pharmacodynamics and pharmacokinetics of many medicaments used in clinical care.
David R. Skvarc +5 more
doaj +1 more source
Apolipoprotein E Genotyping for Pharmacogenetic Purposes in Alzheimer's Disease: Emerging Ethical Issues [PDF]
, 2000 Amalia M. Issa, Edward W. Keyserlingk
openalex +1 more source
Pharmacogenetics for the prescriber
Medicine, 2012 Pharmacogenetics is the study of how genetic factors affect the response to drugs (efficacy, adverse effects). Variation in genes can affect either a drug's pharmacokinetics (how the drug is handled in the body) or its pharmacodynamics (how it interacts with proteins in the body to produce its effects).
openaire +2 more sources
Pharmacogenetics of catechol-O-methyltransferase: Frequency of low activity allele in a Ghanaian population [PDF]
, 2000 Margaret‐Mary Ameyaw +4 more
openalex +1 more source
Alimentary Pharmacology &Therapeutics, Volume 62, Issue 6, Page 630-645, September 2025.Carriage of any loss of function NUDT15 varaint is associated with an increased risk of thiopurine‐induced myelosuppression. Pre‐treatment genotype testing of NUDT15. ABSTRACT Background The clinical utility and cost‐effectiveness of pre‐thiopurine NUDT15 pharmacogenetic testing in European and admixed populations are unknown.
Christopher Roberts +34 more
wiley +1 more source